On October 26, 2023, Venus Remedies announced a significant achievement – the granting of market authorization in the United Kingdom for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion by its German subsidiary, Venus Pharma GmbH. This remarkable milestone not only expands the pharmaceutical giant’s global presence but also underscores its commitment to advancing cancer …